Gregor Zemljic

Dr. Gregor Zemljic

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2007 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
GZGregor Zemljic
Gregor Zemljic
MBMatjaz Bunc
Matjaz Bunc
AYAria P. Yazdanbakhsh
Aria P. Yazdanbakhsh
BVBojan Vrtovec
Bojan Vrtovec

1 August 2014 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
GPGregor Poglajen
Gregor Poglajen
MSMatjaz Sever
Matjaz Sever
MCMarko Cukjati
Marko Cukjati
PCPeter Cernelc
Peter Cernelc
IKIvan Knezevic
Ivan Knezevic
BVBojan Vrtovec
Bojan Vrtovec
Background—: We investigated the effects of transendocardial CD34 + cell transplantation in patients with ischemic cardiomyopathy. Methods and Results—: In a prospective crossover study, we enrolled 33 patients with ischemic cardiomyopathy with New York Heart Association class III and left ventricular ejection fraction <40%. In phase 1, patients were treated with medical therapy for 6 months. Thereafter, all patients underwent transendocardial CD34 + cell transplantation. Peripheral blood CD34 + cells were mobilized by granulocyte colony stimulating factor, collected via apheresis, and injected transendocardially in the areas of hibernating myocardium. Patients were followed up for 6 months after the procedure (phase 2). Two patients died during phase 1 and none during phase 2. The remaining 31 patients were 85% men, aged 57±6 years. In phase 1, we found no change in left ventricular ejection fraction (from 25.2±6.2% to 27.1±6.6%; P =0.23), N-terminal pro B-type natriuretic peptide (from 3322±3411 to 3672±5165 pg/mL; P =0.75) or 6-minute walk distance (from 373±68 to 411±116 m; P =0.17). In contrast, in phase 2 there was an improvement in left ventricular ejection fraction (from 27.1±6.6% to 34.9±10.9%; P =0.001), increase in 6-minute walk distance (from 411±116 to 496±113 m; P =0.001), and a decrease in N-terminal pro B-type natriuretic peptide (from 3672±5165 to 1488±1847 pg/mL; P =0.04). The average number of injected CD34 + cells was 90.6±7.5×10 6 . Higher doses of CD34 + cells and a more diffuse distribution of transendocardial cell injections were associated with better clinical response. Conclusions—: Transendocardial CD34 + cell transplantation may be associated with improved left ventricular function, decreased N-terminal pro B-type natriuretic peptide levels, and better exercise capacity in patients with ischemic cardiomyopathy. These effects seem to be particularly pronounced in patients receiving diffusely distributed cell injections and high-dose cell therapy. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01350310.

29 March 2016 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
BVBojan Vrtovec
Bojan Vrtovec
MSMatjaz Sever
Matjaz Sever
MJMojca Jensterle
Mojca Jensterle
GPGregor Poglajen
Gregor Poglajen
AJAndrej Janez
Andrej Janez
UJUlrich P. Jorde
Ulrich P. Jorde
We evaluated the association of diabetes and insulin resistance with the response to cell therapy in patients with nonischemic dilated cardiomyopathy (DCM). A total of 45 outpatients with DCM received granulocyte colony-stimulating factor for 5 days. CD34+ cells were then collected by apheresis and injected transendocardially. Twelve patients had diabetes mellitus (DM group), 17 had insulin resistance (IR group), and 16 displayed normal glucose metabolism (no-IR group). After stimulation, we found higher numbers of CD34+ cells in the IR group (94 ± 73 × 106 cells per liter) than in the no-IR group (54 ± 35 × 106 cells per liter) or DM group (31 ± 20 × 106 cells per liter; p = .005). Similarly, apheresis yielded the highest numbers of CD34+ cells in the IR group (IR group, 216 ± 110 × 106 cells; no-IR group, 127 ± 82 × 106 cells; DM group, 77 ± 83 × 106 cells; p = .002). Six months after cell therapy, we found an increase in left ventricular ejection fraction in the IR group (+5.6% ± 6.9%) and the no-IR group (+4.4% ± 7.2%) but not in the DM group (−0.9% ± 5.4%; p = .035). The N-terminal pro-brain natriuretic peptide levels decreased in the IR and no-IR groups, but not in the DM group (−606 ± 850 pg/ml; −698 ± 1,105 pg/ml; and +238 ± 963 pg/ml, respectively; p = .034). Transendocardial CD34+ cell therapy appears to be ineffective in DCM patients with diabetes. IR was associated with improved CD34+ stem cell mobilization and a preserved clinical response to cell therapy. Significance: The present study is the first clinical study directly evaluating the effects of altered glucose metabolism on the efficacy of CD34+ stem cell therapy in patients with nonischemic dilated cardiomyopathy. The results offer critical insights into the physiology of stem cell mobilization in heart failure and possibly an explanation for the often conflicting results obtained with stem cell therapy for heart failure. These results demonstrate that patients with dilated cardiomyopathy and diabetes do not benefit from autologous CD34+ cell therapy. This finding could serve as a useful tool when selecting heart failure patients for future clinical studies in the field of stem cell therapy.

11 March 2017 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
MBMojca Bervar
Mojca Bervar
MKMirta Kozelj
Mirta Kozelj
GPGregor Poglajen
Gregor Poglajen
MSMatjaz Sever
Matjaz Sever
GZGregor Zemljic
Gregor Zemljic
BVBojan Vrtovec
Bojan Vrtovec
We sought to evaluate the physiological background and the effects of CD34+ cell transplantation on diastolic parameters in nonischemic dilated cardiomyopathy patients (DCM). We enrolled 38 DCM patients with NYHA class III and LVEF <40% who underwent transendocardial CD34+ cell transplantation. Peripheral blood CD34+ cells were mobilized by G-CSF, collected via apheresis, and injected transendocardially in the areas of myocardial hibernation. Patients were followed for 1 year. At baseline, estimated filling pressures were significantly elevated (E/e'≥15) in 18 patients (Group A), and moderately elevated (E/e'<15) in 20 patients (Group B). The groups did not differ in age (54 ± 9 years vs. 52 ± 10 years; p = .62), gender (male: 85% vs. 78%; p = .57), or LVEF (31 ± 7% vs. 34 ± 6%; p = .37). When compared to Group B patients in Group A had more segments with myocardial scar (4.9 ± 2.7 vs. 2.7 ± 2.9; p = .03), myocardial hibernation (2.2 ± 1.6 vs. 0.9 ± 1.1; p = .02), and longer average local relaxation time on electroanatomical mapping (378 ± 41 ms vs. 333 ± 34 ms, p = .01). During follow-up there was an improvement in diastolic parameters in Group A (E/e': from 24.3 ± 12.1 to 16.3 ± 8.0; p = .005), but not in Group B (E/e': from 10.2 ± 3.7 to 13.2 ± 9.1; p = .19). Accordingly, in Group A, we found an increase in 6-minute walk distance (from 463 ± 83 m to 546 ± 91 m; p = .03), and a decrease in NT-proBNP (from 2140 ± 1743 pg/ml to 863 ± 836 pg/ml; p = .02). In nonischemic DCM, diastolic dysfunction appears to correlate with areas of myocardial scar and hibernation. Transendocardial CD34+ cell transplantation may improve diastolic parameters in this patient cohort. © Stem Cells Translational Medicine 2017

4 December 2009 in Journal of Cardiovascular Pharmacology and Therapeutics
Verified
Journal Article
Closed access
PDF file
GZGregor Zemljic
Gregor Zemljic
MBMatjaz Bunc
Matjaz Bunc
BVBojan Vrtovec
Bojan Vrtovec
Background: Trimetazidine improves functional class and left ventricular function in patients with heart failure; however, its potential impact on QTc interval remains undefined. We analyzed the effects of trimetazidine on QTc interval in patients with ischemic heart failure. Methods: A prospective trial included 42 patients with ischemic heart failure (New York Heart Association [NYHA] 2 or 3) and reduced left ventricular ejection fraction (440 milliseconds) baseline QTc interval (—45 ± 38 milliseconds) than in patients with normal QTc interval (—19 ± 19 milliseconds P = .04). Significant QTc interval shortening (>20 milliseconds) was present in 14 of 22 patients (64%) in trimetazidine group compared to 3 of 20 (15%) patients in control group (P = .002). Conclusions: Trimetazidine therapy is associated with QTc interval shortening in patients with ischemic heart failure.

11 August 2016 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
PDF file
GZGregor Zemljic
Gregor Zemljic
GPGregor Poglajen
Gregor Poglajen
MSMatjaz Sever
Matjaz Sever
MCMarko Cukjati
Marko Cukjati
SFSabina Frljak
Sabina Frljak
BVBojan Vrtovec
Bojan Vrtovec